Johannes Aebi

TL;DR: The target protein with an inhibitor that showed cholesterol lowering in vivo opens the way for the structure-based design of new OSC inhibitors, and the complex with the reaction product lanosterol gives a clear picture of the way in which the enzyme achieves product specificity in this highly exothermic cyclization reaction.

TL;DR: Steroselective alkylation at C(α) of Serine, Clyceric acid, Threonine, and Tartaric acid Involving Heterocyclic Enolates with Evocyelic double bonds as discussed by the authors.

TL;DR: Findings clearly differentiate the OSC inhibitor Ro 48-8.071 from simvastatin, and support the view that OSC is a distinct key component in the regulation of the cholesterol synthesis pathway.

TL;DR: The pure methyl esters of the heterocyclic carboxylic acids specified in the title were prepared in several steps by known methods from aspartic and glutamic acid, with overall yields of ca. 20%.

TL;DR: The approach combined testing of the compounds first for increased binding affinity and for increased stability in vitro, and most promising compounds were then evaluated for their efficacy in lowering plasma total cholesterol (TC) and plasma low-density lipoprotein cholesterol (LDL-C) in hyperlipidemic hamsters.